Neoantigen immunogenicity prediction is a burgeoning field with vast potential; however, the shortage of high-quality data and biases in current datasets limit model generalizability. Here we discuss some of the pitfalls that may underly this limited performance and propose a path forward.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Reassessing human MHC-I genetic diversity in T cell studies
Scientific Reports Open Access 04 April 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
15 April 2024
A Correction to this paper has been published: https://doi.org/10.1038/s43018-024-00767-4
References
Rosenberg, S. A., Parkhurst, M. R. & Robbins, P. F. Cancer Cell 41, 646–648 (2023).
Koşaloğlu-Yalçın, Z. et al. Nucleic Acids Res. 51, D845–D852 (2022).
Bruno, P. M. et al. Nat. Biotechnol. 1, 980–992 (2023).
Holm, J. S. et al. Nat. Commun. 13, 1935 (2022).
Gfeller, D. et al. Cell Syst. 14, 72–83.e5 (2023).
Albert, B. A. et al. Nat. Mach. Intell. 5, 861–872 (2023).
Gartner, J. J. et al. Nat. Cancer 2, 563–574 (2021).
Motmaen, A. et al. Proc. Natl Acad. Sci. USA 120, e2216697120 (2023).
Wolf, Y. et al. Cell 179, 219–235.e21 (2019).
Martínez-Jiménez, F. et al. Nat. Genet. 55, 820–831 (2023).
McGranahan, N. et al. Cell 171, 1259–1271.e11 (2017).
Chowell, D. et al. Nat. Med. 25, 1715–1720 (2019).
Deng, L. et al. Front. Immunol. https://doi.org/10.3389/fimmu.2023.1128326 (2023).
Cattaneo, C. M. et al. Nat. Biotechnol. 41, 783–787 (2023).
Yu, B. et al. Cell 185, 4904–4920.e22 (2022).
Acknowledgements
This work is part of the DECOD-Ag project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 964998. This publication reflects only the author’s view and the European Commission is not responsible for any use that may be made of the information it contains.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
S.A.Q. is co-founder and chief scientific officer and own shares in Achilles Therapeutics. C.S. acknowledges grants from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Roche-Ventana, Invitae (previously Archer Dx Inc., a collaboration in minimal residual disease sequencing technologies), Ono Pharmaceutical and Personalis. He is chief investigator for the AZ MeRmaiD 1 and 2 clinical trials and is the steering committee chair. He is also co-chief investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s scientific advisory board (SAB). He receives consultant fees from Achilles Therapeutics (also an SAB member); Bicycle Therapeutics (also an SAB member); Genentech; Medicxi; the China Innovation Centre of Roche (CICoR), formerly Roche Innovation Centre Shanghai; Metabomed (until July 2022); Relay Therapeutics; and the Sarah Cannon Research Institute. C.S has received honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Illumina, MSD, Novartis, Pfizer and Roche-Ventana; previously held stock options in Apogen Biotechnologies and GRAIL; currently has stock options in Epic Bioscience and Bicycle Therapeutics; and has stock options and is co-founder of Achilles Therapeutics. S.R.H. is the cofounder of PokeAcell and is co-inventor of licensed patents related to T cell detection. H.O’B., M.S., L.M. and F.O’F. are employees of Achilles Therapeutics.
Rights and permissions
About this article
Cite this article
O’Brien, H., Salm, M., Morton, L.T. et al. Breaking the performance ceiling for neoantigen immunogenicity prediction. Nat Cancer 4, 1618–1621 (2023). https://doi.org/10.1038/s43018-023-00675-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00675-z
This article is cited by
-
Reassessing human MHC-I genetic diversity in T cell studies
Scientific Reports (2024)